Answers are grounded in this paper and cite their sources.
Retrospective study finds that lower CD8 T-cell counts predict better survival in DLBCL patients, indicating immune status importance.
While the prognostic significance of peripheral blood (PB) lymphocyte counts in diffuse large B-cell lymphoma (DLBCL) patients treated with Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Prednisone (R-CHOP) is established, the specific role of CD8+ T-cell counts (CD8c) remains unclear. Methods: This retrospective study analyzed 315 newly diagnosed DLBCL patients treated at Central Hospital of Xiangtan from January 2018 to September 2023. We evaluated the prognostic significance of initial CD8c and other clinical parameters using univariate and multivariate survival analyses to identify independent predictors of outcome. An optimal CD8c cut-off value of 264.5×106/L was identified. Low CD8c correlated with significantly improved 5-year progression-free survival (PFS) (88.78% vs 49.18%, p<0.001) and overall survival (OS) (84.02% vs 31.25%, p<0.001). Multivariate analysis confirmed CD8c as an independent prognostic factor for both PFS and OS. CD8c demonstrated significant interactions with lactate dehydrogenase levels. Notably, low CD8c groups consistently exhibited superior survival outcomes, even in the presence of other poor prognostic factors. Initial PB CD8c serves as an independent predictor for R-CHOP-treated DLBCL patients. These findings suggest CD8c may be a candidate for enhancing existing prognostic models, particularly when combined with established risk factors, underscoring the potential importance of host immune status in DLBCL prognosis and treatment outcomes. Independent validation in external cohorts is needed. Diffuse large B-cell lymphoma (DLBCL) is an aggressive blood cancer. While the standard R-CHOP therapy is effective, outcomes vary widely. Current models to predict prognosis are not fully accurate. The immune system plays a crucial role in fighting cancer, but the specific predictive value of a key immune cell, the CD8 + T-cell, in the blood of DLBCL patients at diagnosis was not well understood. This study analyzed 315 DLBCL patients receiving R-CHOP therapy. We discovered that a lower count of CD8 + T-cells in the blood at diagnosis was a strong predictor of better survival. This finding was surprising, as these cells normally fight cancer. Crucially, this CD8 + T-cell count was an independent factor, meaning its predictive power held true even when accounting for other established risk factors. This research suggests that a simple, routine blood test measuring CD8 + T-cell counts can significantly improve how doctors predict a DLBCL patient’s prognosis. It highlights the critical role of the patient’s immune status, paving the way for more personalized treatment plans and better-informed patient care.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: